BIO-TECHNE Corp (TECH) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$72.51

From 52W high−0.17%

Volume2.57M

Market cap$11.37B

P/E (TTM)62.0x

P/S (TTM)9.4x

Div yield0.44%

Key dataOct 19, 2026

Open

$72.51

From 52W high

−0.17%

Volume

2.57M

Market cap

$11.37B

ValuationView details →

P/E (Fwd)

34.1x

EV/EBITDA

33.2x

P/E (TTM)

62.0x

RSI (14)

54.9

MomentumView details →

1D Return

−0.11%

YTD Return

+23.29%

SummaryUpdated Jun 1, 2026

Bio-Techne Corporation (NASDAQ:TECH) is a Minneapolis-based biotechnology company founded in 1976 that develops, manufactures, and sells life science research tools and diagnostic products worldwide. Originally known as Techne Corporation until 2014, the company has grown through strategic acquisitions and organic expansion to become a leading provider of biological reagents, instruments, and services serving the research and clinical diagnostic markets. Bio-Techne operates through two primary business segments and has established itself as a critical supplier to pharmaceutical companies, biotechnology firms, academic institutions, and clinical laboratories globally.

Ask drillr about BIO-TECHNE Corp →

ValuationView details →

P/E (Fwd)

34.1x

P/E (TTM)

62.0x

EV/EBITDA

33.2x

EV/Sales

9.4x

P/S (TTM)

9.4x

P/B (TTM)

5.4x

ProfitabilityView details →

Gross Margin

65.77%

Net Margin

14.97%

EBITDA Margin

28.27%

ROE (TTM)

8.63%

ROA (TTM)

7.03%

Asset Turnover

0.47x

GrowthView details →

Revenue YoY

−0.38%

EPS YoY

+154.35%

FCF YoY

+2.60%

Revenue CAGR 3Y

+2.25%

EPS CAGR 3Y

−13.54%

EBITDA YoY

+58.36%

MomentumView details →

1D Return

−0.11%

YTD Return

+23.29%

1Y Return

+15.93%

RSI (14)

54.9

vs 50D SMA

+0.16%

vs 200D SMA

+15.43%

Capital & dividendView details →

Debt/Equity

0.14x

Current Ratio

4.55x

Quick Ratio

3.35x

Div Yield

0.44%

Div Rate

$0.32

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.52

EPS Surprise

0.19%

Beats (12Q)

6/12

Next Q EPS Est

$0.47

Avg Surprise (4Q)

0.80%

Rev Surprise

2.09%

Financials snapshotView financials →

Revenue (TTM)

1.22B

Net Income (TTM)

181.86M

Op. CF (TTM)

292.07M

Next earningsNov 4, 2026 →

Latest newsMore news →

Bio-Techne shareholders voted to approve the definitive merger agreement under which Merck KGaA, Darmstadt, Germany would acquire Bio-Techne, at a special meeting held on September 23, 2026.26d ago

Bio-Techne Corporation opened a new Customer Experience Center in Düsseldorf, Germany, to serve researchers across the DACH and EMEA regions.27d ago

Similar companies

欧林生物688319.SH 诺唯赞688105.SH Duality Biotherapeutics, Inc.09606.HK Everest Medicines Limited01952.HK Corcept Therapeutics IncorporatedCORT Mabwell-b02493.HK Find similar companies →

Latest newsMore news →

Bio-Techne shareholders voted to approve the definitive merger agreement under which Merck KGaA, Darmstadt, Germany would acquire Bio-Techne, at a special meeting held on September 23, 2026.26d ago Bio-Techne Corporation opened a new Customer Experience Center in Düsseldorf, Germany, to serve researchers across the DACH and EMEA regions.27d ago